7 terminated. 7 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Terminated 7 |
| Phase 2 | 3 | Terminated 3 |
Follow Myelitis: new trials by email Literature Review of Myelitis trials Research Report on Myelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 5 | 2020-01-14 | 2024-09-25 |
| A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM) KW-0761 0.3 mg/kg IV, Placebo (saline) - HTLV-1 Associated Myelopathy | Phase 3 | Terminated | Kyowa Kirin Co., Ltd. | 66 | 2017-05-22 | 2022-04-14 |
| A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Intravenous Methylprednisolone, Intravenous Immunoglobulin - Myelitis, Transverse, Neuromyelitis Optica | Phase 3 | Terminated | Guy's and St Thomas' NHS Foundation Trust | 2 | 2015-03-01 | 2016-07-20 |
| Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome Flebogamma® 5% DIF, Placebo - Post-polio Syndrome | Phase 2 / Phase 3 | Terminated | Instituto Grifols, S.A. | 191 | 2014-09-23 | 2025-12-05 |
| A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) Eculizumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 143 | 2014-04-11 | 2019-06-26 |
| Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Tamibarotene - HTLV-I-Associated Myelopathy | Phase 2 / Phase 3 | Terminated | St. Marianna University School of Medicine | 15 | 2011-01-01 | 2026-10-08 |
| Modafinil to Treat Fatigue in Post-Polio Syndrome Modafinil - Postpoliomyelitis Syndrome | Phase 3 | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | 30 | 2003-08-01 | 2008-08-27 |
Myelitis, Transverse (3) · Neuromyelitis Optica (3) · Demyelinating Diseases (2) · Optic Neuritis (2) · Paraparesis, Tropical Spastic (2) · Postpoliomyelitis Syndrome (2) · Recurrence (2) · Asthenia (1) · Depression (1) · Pain (1) · Poliomyelitis (1) · Sleep Apnea Syndromes (1)
Central Nervous System Diseases (7) · Central Nervous System Infections (7) · Infections (7) · Nervous System Diseases (7) · Neuroinflammatory Diseases (7) · Spinal Cord Diseases (7) · Neurodegenerative Diseases (5) · RNA Virus Infections (4) · Virus Diseases (4) · Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (3) · Cranial Nerve Diseases (3) · Demyelinating Autoimmune Diseases, CNS (3) · Eye Diseases (3)
Immunoglobulins, Intravenous (2) · eculizumab (2) · Modafinil (1) · Sodium Chloride (1) · gamma-Globulins (1) · mogamulizumab (1) · tamibarotene (1)
Alexion Pharmaceuticals, Inc. (2) · Guy's and St Thomas' NHS Foundation Trust (1) · Instituto Grifols, S.A. (1) · Kyowa Kirin Co., Ltd. (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · St. Marianna University School of Medicine (1)
Japan (4) · United States (4) · Germany (3) · Italy (3) · Spain (3) · Canada (2) · Czechia (2) · Denmark (2) · South Korea (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Croatia (1) · Hong Kong (1) · Malaysia (1)
Marinos Dalakas, MD (1) · Ming Lim, MB, PhD (1) · Yoshihisa Yamano, MD (1)
PMID 26009577, PMID 28639937, PMID 31050279, PMID 33310418, PMID 33676197, PMID 34498507, PMID 34803867, PMID 38430272
2014 (1), 2019 (1)